Skip to main content
Premium Trial:

Request an Annual Quote

Affibody Names New CEO; Ciphergen Loses Another CFO; Hakonarson to Leave Decode; and Others

Affibody named Ulf Boberg as its new chief executive officer this week. The appointment is effective June 1.

 

He replaces Carl-Johan Dalsgaard, who has been acting CEO since December 2005. Dalsgaard is a partner of Affibody's largest shareholder, HealthCap, and will remain a non-executive Affibody director.

 

Boberg came to Affibody in January 2006 as senior vice-president for development. Prior to that, he was CEO of Global Genomics AB. He also held the senior roles of vice president and head of the development division at Astra Pain Control, vice president and R&D site general manager at AstraZeneca, head of medical research at Gambro, CEO of PMC Clinical Research AB, and CEO of Alfta Rehab Center.


Daniel Caserza, interim chief financial officer of Ciphergen Biosystems, is expected to resign today, according to documents filed with the Securities and Exchange Commission early this week. He became the interim CFO in March after Matthew Hogan abruptly resigned.

 

Gail Page, the company's president and chief executive officer, will act as interim chief financial officer until the company finds a permanent replacement.

 

Ciphergen has hired the Financial Leadership Group to help it prepare financial statements until a replacement is appointed.


Illumina appointed Christian Cabou as senior vice president and general counsel, the company said this week.

 

Most recently, Cabou spent five years as general counsel of GE Global Research. Earlier, he was senior counsel of global intellectual property of GE Medical Systems. He also spent nearly seven years with the firm of Foley & Lardner, where he was a partner.

 

Cabou received his JD from Northwestern University School of Law in Chicago. He received a master of engineering management from Northwestern and a MSEE degree from the Conservatoire National des Arts et Metiers  in Paris, and a BS from the Lycee Technique d'Etat in Armentieres, France.


Stephen Scherer has joined CombiMatrix Molecular Diagnostics' science advisory board.

 

Scherer is a senior scientist in genetics and genomic biology at The Hospital for Sick Children in Canada and associate professor of medicine at the University of Toronto. He is also director of the Centre for Applied Genomics and associate chief of research at the hospital.

 

CombiMatrix Molecular Diagnostics is wholly owned by CombiMatrix.


Archemix named to its board of directors John Maraganore, the president and chief executive officer of Alnylam Pharmaceuticals, the company said Wednesday.

 

Prior to becoming Alnylam's CEO, Maraganore was senior vice-president of strategic product development for Millennium Pharmaceuticals, vice president of strategic planning and M&A, and general manager of Millennium BioTherapeutics, a former subsidiary of Millennium.

 

Maraganore is a director of the Biotechnology Industry Organization.


Hakon Hakonarson is leaving Decode Genetics to pursue other interests, the company said earlier this week.

 

Hakonarson has been with Decode for eight years and held various positions, most recently as vice president of business development.

 

Tomas Sigurdsson, Decode's vice president of treasury and new alliances, will assume responsibility for the company's business development

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.